Schizophrenia, dissociative anaesthesia and near-death experience; three events meeting at the NMDA receptor

Medical Hypotheses

Volumn 62, Issue 1, 2004, Pages 23-28

  Bonta, Iván L ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOSERINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; EXCITATORY AMINO ACID RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLYCINE; GLYCINE RECEPTOR; HALOPERIDOL; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; SEROTONIN 2 RECEPTOR;

AMINO ACID SEQUENCE; ANESTHESIA; ANIMAL BEHAVIOR; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; DEATH; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; EUPHORIA; HUMAN; IN VIVO STUDY; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; SEQUENCE ANALYSIS; SYNAPTOSOME;

EID: 1042277735     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(03)00307-4     Document Type: Article

References (30)

1. Sucher NJ, Awobuluyi M, Choi Y-B, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996;17:348-55.
2. Meldrum BS, Chapman AG. Competitive NMDA antagonists as drugs. In: Collingridge GL, Watkins JC, editors. The NMDA receptor. 2nd ed. Oxford: Oxford University Press; 1994. p. 457-68.
3. Iversen LL, Kemp JA. Non-competitive NMDA antagonists as drugs. In: Collingridge GL, Watkins JC, editors. The NMDA receptor. 2nd ed. Oxford: Oxford University Press; 1994. p. 469-86.
4. Bonta IL, de Vos CJ, Grijsen H, Hillen FC, Noach EL, Sim AW. 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases. Brit J Pharmacol 1971;43:514-35.
5. 2+-like antagonism of excitatory amino acid-induced responses by D-aminopimelic acid, D-amino adipate and HA-966 in isolated spinal cord of frog and immature rat. Brain Res 1978;148: 536-42.
6. Watkins JC, Olverman H. Structural requirements for activation and blockade of EAA receptors. In: Lodge D, editor. Excitatory amino acids in health and disease. London: Wiley; 1988. p. 13-45.
7. Fletcher EJ, Lodge D. Glycine reverses antagonism of N-methyl-D- aspartate (NMDA) by 1-hydroxy-3-amino-pyrrolidone-2 (HA-966) but not by D-2-amino-phosphonovalerate (D-AP5) on rat cortical slices. Eur J Pharmacol 1988;151: 161-2.
8. Kemp JA, Priestley T, Woodruff GN. Differences in the N-methyl-D-aspartate antagonist profiles of two compounds acting at the glycine modulatory site. Brit J Pharmacol 1988;95:759P.
9. Kemp JA, Priestley T. Effects of (+)HA-966 and 7-chlorokynurenic acid on the kinetics of N-methyl-D-aspartate receptor response in rat cultured cortical cells. Mol Pharmacol 1991;39:666-70.
10. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind controlled comparison of the novel antipsychotic olanzepine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatr 1998;155:751-60.
11. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Pharmacol Sci 1992;13:113-21.
12. Herrling PL. Clinical implications of NMDA receptors. In: Collingridge GL, Watkins CJ, editors. The NMDA receptor. 2nd ed. Oxford: Oxford University Press; 1994. p. 381-2.
13. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatr 1999;56:29-36.
14. Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about schizophrenia? Arch Gen Psychiatr 1999;56:13-7.
15. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to concentional neuroleptics, olanzepine, or risperidone in schizophrenia. Am J Psychiatr 2002;159:480-2.
16. Singh L, Donald AE, Foster AC, et al. Enantiomers of HA-966 (3-amino-1-hydroxy pyrrolid-2-on) exhibit distinct central nervous system effects: (+)Ha-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (-)HA-966 is a potent γ-butyrolactone-like sedative. Proc Natl Acad Sci USA 1990;87:347-51.
17. Kemp JA, Priestley T, Marshall GR, Leeson PD, Williams BJ. Functional assessment of the actions of 4-methyl derivatives of HA-966 at the glycine site of the N-methyl-D-aspartate receptor. Brit J Pharmacol 1991;102(Proc. Suppl):65P.
18. Javitt DC. Glycine modulators of schizophrenia. Curr Opin Investig Drugs 2002;3:1067-122.
19. Wong EHF, Kemp JA. Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Ann Rev Pharmacol Toxicol 1991;31:401-25.
20. Harris RA, Mihic SJ, Dildy-Mayfield JE, Mahu TK. Actions of anesthetics on ligand-gated ion channels: role of receptor subunit composition. FASEB J 1995;9:1454-62.
21. Oye N, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992;260: 1209-13.
22. Krystal JH, Karoer LP, Seibyl JP, et al. Subanaesthetic effects of the noncompetitive antagonist, ketamine, in humans. Arch Gen Psychol 1994;51:199-214.
23. Kumlien E, Hartvig P, Valind S, Øye I,Tedroff J, Långström B. NMDA-receptor activity visualized with (S)-[N-methyl-11C] ketamine and positron emission tomography in patients with medial temporal lobe epilepsy. Epilepsia 1999;40:30-7.
24. Greyson B, Stevenson I. The phenomenology of near-death experience. Am J Psychol 1980;137:1193-200.
25. Blacher RS. The near-death experience. J Am Med Ass 1980;244:1930.
26. Carr DB. Endorphins at the approach of death. Lancet 1981;1:390.
27. Jansen KLR. Neuroscience and the near-death experience: roles for the NMDA-PCP receptor, the sigma receptor and the endopsychosins. Med Hypotheses 1990;31:25-9.
28. Webster's Unabridged Dictionary of the English Language. Random House Value Publishing Inc. 1996.
29. Abi-Saab WM. The NMDA antagonist model of schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31(Suppl 2):104-9.
30. Javitt DC, Sershen H, Hashim A, Lajtha A. Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology 1997;17:202-4.